Description
PF-03758309 is an ATP-competitive inhibitor of p21-activated kinase 4 (PAK4), a kinase typically upregulated in many cancers. This compound exhibits anticancer chemotherapeutic and anti-metastatic activities. Inhibition of PAK4 inhibits cell motility, proliferation, and survival in cellular models of cancer and suppresses tumor growth in animal models of cancer. PF-03758309 also inhibits fusion and migration of preosteoclasts, osteoclast differentiation, and podosome formation in cellular models of osteoclast-related disorders.